Department of Neurology, Konyang University College of Medicine, Konyang University Hospital, Daejeon, South Korea.
Department of Preventive Medicine, Ulsan University College of Medicine, Seoul, South Korea.
BMC Geriatr. 2022 Apr 22;22(1):353. doi: 10.1186/s12877-022-03028-0.
Dementia is a common feature in Parkinson's disease (PD); however, data on dementia treatment patterns in patients with PD are scarce. This study aimed to evaluate the incidence of dementia in individuals with PD and to describe the dementia treatment patterns in the Korean elderly population.
We conducted a retrospective population-based cohort study using data obtained from the Korean National Health Insurance Service-Senior Cohort (NHIS-SC) database. The dataset comprised more than 500,000 health insurance beneficiaries from January 1, 2002 to December 31, 2015. We estimated the incidence of patients newly diagnosed with dementia during this observational period, compared patient demographics, and analyzed the exposure to anticholinergic drugs among PD patients with (PD + D) and without (PD-D) dementia. Furthermore, the duration to dementia diagnosis and patterns of dementia treatment were evaluated.
A cohort of 28,537 patients aged 60 years or older who were diagnosed with PD by the NHIS was established. Within this cohort, 8620 patients were eligible study participants according to strict inclusion/exclusion criteria. Of these individuals, 3879 (45.0%) patients were newly diagnosed with dementia; the incidence of dementia in PD was 15.2 per 1000 person-years. The proportion of women was higher in the PD + D (64.6%) than the PD-D group (58.2%) (P < 0.001); furthermore, the use of anticholinergic medication was greater in PD + D (37.6%) than in PD-D (24.0%) patients. The incidence curves for dementia over time were the steepest during the first year and decreased every year thereafter. Approximately 60% of PD patients were diagnosed with dementia during the first 3 years. Regarding the use of anti-dementia drugs, 2539 (65.5%) of 3879 PD + D were prescribed medication. During the observation period, 1799 (70.9%) patients were prescribed only one type of anti-dementia drug. In this monotherapy group, the most commonly prescribed medication was donepezil (1313[73.0%]), followed by rivastigmine (capsule and patch; 246[13.7%]), memantine (187[10.4%]), and galantamine (53[2.9%]).
In Korea, dementia was observed to occur relatively soon after the diagnosis of PD. Anti-dementia medication was prescribed to approximately 66% of PD + D patients, with the majority receiving donepezil as monotherapy.
痴呆是帕金森病(PD)的常见特征;然而,关于 PD 患者痴呆治疗模式的数据很少。本研究旨在评估 PD 个体中痴呆的发生率,并描述韩国老年人群的痴呆治疗模式。
我们使用来自韩国国家健康保险服务-老年队列(NHIS-SC)数据库的数据进行了一项回顾性基于人群的队列研究。该数据集包含 2002 年 1 月 1 日至 2015 年 12 月 31 日期间 50 多万名健康保险受益人的信息。我们估计了在此观察期间新诊断为痴呆的患者的发病率,比较了患者的人口统计学特征,并分析了 PD 患者(PD+D)和无痴呆(PD-D)患者中抗胆碱能药物的暴露情况。此外,评估了痴呆诊断的时间和痴呆治疗模式。
建立了一个由 28537 名 60 岁或以上被 NHIS 诊断为 PD 的患者组成的队列。在该队列中,根据严格的纳入/排除标准,有 8620 名患者符合入选研究的条件。在这些人中,3879 名(45.0%)患者被新诊断为痴呆;PD 的痴呆发生率为每 1000 人年 15.2 例。PD+D 组(64.6%)女性比例高于 PD-D 组(58.2%)(P<0.001);此外,PD+D 组(37.6%)比 PD-D 组(24.0%)患者更常使用抗胆碱能药物。随着时间的推移,痴呆的发病率曲线在第一年最为陡峭,此后每年都有所下降。大约 60%的 PD 患者在头 3 年内被诊断为痴呆。关于使用抗痴呆药物,3879 名 PD+D 中有 2539 名(65.5%)患者接受了药物治疗。在观察期间,1799 名(70.9%)患者仅使用了一种类型的抗痴呆药物。在该单药治疗组中,最常开的药物是多奈哌齐(1313[73.0%]),其次是利斯的明(胶囊和贴片;246[13.7%])、美金刚(187[10.4%])和加兰他敏(53[2.9%])。
在韩国,PD 诊断后不久就观察到痴呆的发生。大约 66%的 PD+D 患者接受了抗痴呆药物治疗,其中大多数患者接受多奈哌齐单药治疗。